Browse > Article

Safety and Effectiveness of Long Acting Injectable Antipsychotic Paliperidone Palmitate Treatment in Schizophrenics : A 24-Week Open-Label Study  

Kang, Hyun-Ku (Keyo Medical Foundation Keyo Hospital)
Hahm, Woong (Keyo Medical Foundation Keyo Hospital)
Shon, In-Ki (Keyo Medical Foundation Keyo Hospital)
Paik, In-Ho (Keyo Medical Foundation Keyo Hospital)
Publication Information
Korean Journal of Biological Psychiatry / v.20, no.3, 2013 , pp. 111-117 More about this Journal
Abstract
Objectives We investigated the effectiveness and safety when treated in schizophrenics with paliperidone palmitate, a long acting injectable antipsychotic. Methods This was a 24-week open-label study, performed at one center in Korea. The eligible patients with schizophrenia diagnosed by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria were enrolled. Patients received long-acting paliperidone palmitate injection (234 mg, baseline; 156 mg, week 1 ; then once 4 weeks flexible dosing). Effectiveness assessments were measured by the Positive and Negative Syndrome Scale (PANSS), The Clinical Global Impression Severity Scale (CGI-S), The Personal and Social Performance (PSP) at baseline, week 1, every 4 weeks untill 24 weeks or endpoint. Safety assessments were measured by The Extrapyramidal Symptom Rating Scale (ESRS), body weight (BW) and incidence of adverse events. Oral antipsychotics were stopped or tapered off within next 14 days. Results Of 20 patients recruited, 9 patients (45%) completed the study. Paliperidone palmitate produced a significant improvement in PANSS total score from baseline to endpoint. The response rate was 75% [mean change (${\pm}SD$) $-25.9{\pm}14.4$, all p < 0.001]. The CGI-S and PSP total scores significantly improved during 24 weeks (All p < 0.001). Eighty percent of patients reported adverse events and most common adverse events (${\geq}10%$) in paliperidone palmitate were anticholinergic adverse event, extrapyramidal symptoms, weight gain, akathisia, insomnia, headache, agitation, anxiety and GI trouble. ESRS score is not statistically significant, but tends to get better at the end of the study when compared to baseline. Conclusions Our study results demonstrated maintained effectiveness and safety of paliperidone palmitate treatment in schizophrenics. And provides both clinicians and patients with a new choice of treatment that can improve the outcome of long term therapy. Their potential effectiveness and safety should be better addressed by future randomized-controlled trials.
Keywords
Paliperidone palmitate; Long-acting injection; Effectiveness; Safety; Schizophrenics;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986;6(1 Suppl):2S-10S.   DOI
2 Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-188.   DOI
3 Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-113.   DOI
4 Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-1211.
5 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.   DOI
6 Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009;70:990-996.   DOI
7 Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891.   DOI
8 Ahn YM, Kwon JS, Bahk WM, Kim CE, Park JI, Lee SY, et al. The feasibility test of Korean medication algorithm for the treatment with schizophrenic patients (II): the problem for applying algorithm to the real clinical situation and opinion of revision. Korean J Psychopharmacol 2006;17:35-49.
9 Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64 Suppl 16:14-17.   DOI
10 Shen WW. The need for depot atypical antipsychotics in the U.S. Psychiatr Serv 1998;49:727.   DOI
11 Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433.
12 Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl): 1-56.   DOI
13 Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L [corrected to Matalon L]. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-773.
14 Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45(5 Pt 2):50-59.
15 Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(12 suppl):5-19.   DOI
16 Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow- up of 100 patients. J Clin Psychiatry 2004;65:1076-1083.   DOI
17 Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089.   DOI
18 Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160: 1125-1132.   DOI
19 Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Longacting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005;72:249-258.   DOI
20 Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-796.   DOI
21 Park H, Bae SM, Ryoo JH, Kim SI, Lim WJ. Attitudes of Korean psychiatrists toward treatment long-acting injectable antipsychotic. J Korean Neuropsychiatr Assoc 2009;48:182-189.
22 Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother 2007;8:2307- 2313.   DOI
23 Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs 2010;24:227-244.   DOI
24 Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010;64:216-239.
25 Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009;48:585-600.   DOI
26 Owen RT. Paliperidone palmitate injection: its efficacy, safety and tolerability in schizophrenia. Drugs Today (Barc) 2010;46:463-471.   DOI
27 Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double- blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-256.   DOI
28 Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr 2008;13(5 Suppl 9):1-16.
29 Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q 1994;65:299-322.   DOI
30 American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association;2000.
31 Ortho-McNeil-Janssen Pharmaceuticals Inc. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension: prescribing information [online]. Available from URL: http://www.pharmacy. umaryland.edu/programs/mhaformulary/formulary%20reviews/ pdfs/2009/paliperidoneERinjectable.pdf. Accessed November 20, 2009.
32 Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
33 Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration;1976.
34 Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001;153:238-243.   DOI
35 Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003:16-23.
36 Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSMIV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101:323-329.
37 Kane JM. The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 1984;45(5 Pt 2):5-12.
38 Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, et al. Reliability, validity and ability to detect change of the clinician- rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009;25:325- 338.   DOI
39 Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal rating scale. Can J Neurol Sci 1980;7:233.
40 Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl 1994;382:28-32.
41 Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8:55-66.
42 Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-244.   DOI
43 Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010; 13:635-647.   DOI
44 Lee JS, Kim CY. Efficacy and tolerability of paliperidone palmitate in asian patients with schizophrenia. Korean J Psychopharmacol 2011;22(suppl 2):49-56.